Drug Shortage Report for IRESSA
| Report ID | 257363 |
| Drug Identification Number | 02248676 |
| Brand name | IRESSA |
| Common or Proper name | Gefitinib |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | GEFITINIB |
| Strength(s) | 250MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 50s |
| ATC code | L01XE |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2025-09-01 |
| Estimated end date | 2025-11-15 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-09-16 |
| Company comments | 12345 |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2025-09-16 | English | Compare |
| v3 | 2025-09-16 | English | Compare |
| v2 | 2025-09-16 | French | Compare |
| v1 | 2025-09-16 | English | Compare |
Showing 1 to 4 of 4